HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Enasidenib in People With T-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Status
- RECRUITING
- Phase
- PHASE3
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
- Status
- RECRUITING
- Phase
- PHASE2
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
- Status
- RECRUITING
- Phase
- PHASE3
NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
- Status
- RECRUITING
- Phase
- PHASE1
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
- Status
- RECRUITING
- Phase
- PHASE2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
- Status
- RECRUITING
- Phase
- PHASE2
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
- Status
- RECRUITING
- Phase
- PHASE1
A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Epco, Zanu, Ritux for R/R FL or MZL
- Status
- RECRUITING
- Phase
- PHASE2